Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits
Thrailkill, Kathryn M., Bunn, R. Clay, Uppuganti, Sasidhar, Ray, Philip, Popescu, Iuliana, Kalaitzoglou, Evangelia, Fowlkes, John L., Nyman, Jeffry S.Journal:
Bone
DOI:
10.1016/j.bone.2020.115625
Date:
September, 2020
Fichier:
PDF, 3.24 MB
2020
File converter
Plus de résultats de recherche
More benefits 
